JNJ-75348780 is named as a drug or biological intervention in 2 clinical trials in our UK and China trial registers, none of which are currently recruiting. The lead sponsor is Janssen Research & Development, LLC. Registered phase: Phase 1. Conditions studied include Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06788509 | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (ClinicalTrials.gov ↗) Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin |
Phase 1 | By invitation |
| NCT06660563 | A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) (ClinicalTrials.gov ↗) Lymphoma, Non-Hodgkin |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Lymphoma, Non-Hodgkin | 2 |
| Leukemia, Myeloid, Acute | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Myelodysplastic Syndromes | 1 |
| Lead sponsor | Trials |
|---|---|
| Janssen Research & Development, LLC | 2 |
| Register | JNJ-75348780 trials |
|---|---|
| Clinical trials in UK | 2 |
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how JNJ-75348780 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists JNJ-75348780 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.